-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Facing the international stage, strategically positioning ourselves globally | Keyuan Pharmaceutical Makes a Stunning Debut at the 2024 World Pharmaceutical Ingredients (Japan) Exhibition!
Publish Time:
2024-04-19
Recently, the 2024 International Pharmaceutical Ingredients Exhibition kicked off with great fanfare in Tokyo, Japan. As one of the global benchmarks in the pharmaceutical industry, CPHI draws pharmaceutical companies, research institutions, and industry experts from around the world each year to jointly explore the latest trends and technological innovations shaping the pharmaceutical sector.
Recently, the 2024 International Pharmaceutical Ingredients Exhibition kicked off with great fanfare in Tokyo, Japan. As one of the global benchmarks in the pharmaceutical industry, CPHI draws pharmaceutical companies, research institutions, and industry experts from around the world each year to jointly explore the latest trends and technological innovations shaping the pharmaceutical sector.
As a leading enterprise in China’s niche API sector, Keyuan Pharmaceutical (stock code: 301281.SZ) made a stunning debut at this year’s exhibition, showcasing its exceptional quality, cutting-edge R&D capabilities, and advanced digital manufacturing prowess—elements that have successfully captured the global industry’s attention.
Keyuan Pharmaceutical President Wang Jianwei led his team in strengthening bonds and discussing business opportunities with new and existing customers from around the globe, further advancing future market expansion and collaborative partnerships.
This exhibition not only highlights Keway Pharmaceutical's competitiveness in the international market, but also marks a significant step in the company's global strategic expansion.
In recent years, Keyuan Pharmaceutical has been accelerating its pace of internationalization. Guided by the "One Core, Two Wings, Three Pillars" development strategy, the company is focusing on chronic disease management while actively exploring other specialized niche markets. It continues to deepen its unique advantages in integrated raw material and formulation production, as well as integrated excipient and formulation solutions, while strengthening R&D capabilities, embracing digital and intelligent manufacturing, and advancing culturally driven marketing initiatives. Today, Keyuan Pharmaceutical boasts partnerships spanning dozens of countries and regions worldwide, enabling it to establish a globally comprehensive marketing network.
As the 2024 World Pharmaceutical Ingredients (Japan) Exhibition continues to unfold, Keyuan Pharmaceutical will once again showcase the strength and excellence of Chinese pharmaceutical companies with its outstanding performance.
In the future, the company will continue to participate in world-class international exhibitions, further broadening its global perspective and strengthening communication and collaboration with international partners, thereby contributing to the shared growth of the global pharmaceutical industry.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline